GLP-1 receptor agonists lower serious infections and pneumonia in placebo-controlled trials, which confirm few other associations an observational atlas reported

An observational atlas linked GLP-1 receptor agonists to dozens of outcomes beyond glucose, weight and the heart. We pooled the serious adverse events that 234 placebo-controlled trials of these drugs, with 161309 participants, posted to ClinicalTrials.gov, coded blind to the results under a registered plan. Serious bacterial infections (risk ratio 0.88, confidence interval 0.83 to ) and pneumonia (, to ) were less frequent on the drugs, and stayed so under random effects, a conservative variance and with any trial left out; so was death (). Of the atlas's associations, the trials confirmed , excluded its estimate for , including a large risk of pancreatitis, and lacked the events to test most neurological and psychiatric ones.